You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 40 No. 7, July 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

CSF Dopamine β-Hydroxylase in Schizophrenia

Low Activity Associated With Good Prognosis and Good Response to Neuroleptic Treatment

David E. Sternberg, MD; Daniel P. van Kammen, MD, PhD; Pauline Lerner, PhD; James C. Ballenger, MD; Stephen R. Marder, MD; Robert M. Post, MD; William E. Bunney, Jr, MD

Arch Gen Psychiatry. 1983;40(7):743-747.


Abstract

• Dopamine β-hydroxylase (DBH), the enzyme that converts dopamine to norepinephrine, was measured in the CSF of 30 schizophrenic patients and 27 normal controls. The CSF DBH activity in the patients was not significantly different from that in controls. Levels of CSF DBH activity in individual patients were highly constant over time and were not influenced by clinical state or neuroleptic treatment. Low levels of DBH in CSF did significantly relate to good social and sexual functioning, good prognosis, less symptoms between hospitalizations, and excellent clinical response to neuroleptic treatment. We speculate from these data that low brain DBH activity may produce a type of vulnerability to psychotic decompensation and thereby influence the clinical course, although it does not cause schizophrenia, in general. Low CSF DBH activity may delineate a "reactive" subgroup from the heterogenous population of patients with diagnoses of schizophrenia.



Author Affiliations

From the Section on Neuropsychopharmacology, Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Md. Dr Sternberg is now with Yale University, New Haven, Conn; Dr Ballenger is now with the University of Virginia, Charlottesville; Dr Marder is now with UCLA.


Footnotes

Accepted for publication July 8, 1982.

Reprint requests to Clinical Research Unit, Department of Psychiatry, Yale University, 34 Park St, New Haven, CT 06508 (Dr Sternberg).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dopamine-beta-hydroxylase in postural tachycardia syndrome
Garland et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H684-H690.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.